<- Go Home

Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Market Cap

$15.2B

Volume

541.3K

Cash and Equivalents

$996.7M

EBITDA

$1.8B

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$3.7B

Profit Margin

61.57%

52 Week High

$300.00

52 Week Low

$143.40

Dividend

N/A

Price / Book Value

1.43

Price / Earnings

13.67

Price / Tangible Book Value

3.58

Enterprise Value

$13.4B

Enterprise Value / EBITDA

7.47

Operating Income

$1.2B

Return on Equity

11.17%

Return on Assets

5.49

Cash and Short Term Investments

$1.9B

Debt

$114.3M

Equity

$10.7B

Revenue

$6.1B

Unlevered FCF

-$35.2M

Sector

Biotechnology

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches